Phaseline

Targets › NKG2DL

NKG2DL: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: the race on NKG2DL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Peking University People's HospitalCT0890B
NKG2DL-targeted CAR-T cell therapy
NKG2DLPhase 1AMLDec 2027

Conditions

AML (1)

Modalities

other (1)

Companies

Peking University People's Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.